BioCamp 2022

September 26–30, 2022, **Virtual** Event

New modalities in therapies

Reimagining medicine in the age of metaverse.

Monday, September 26	**Microsoft Teams Meeting link (please click on the link bellow)** Click here to join the meeting	
9:00-12:45		
9:00-9:15	Welcome address	**Robert Ljoljo,** Novartis Country President Slovenia
9:15-9:30	Opening address	**Prof. Gregor Majdič, PhD,** Rector University of Ljubljana
9:30-9:50	Therapies for the treatment of autoimmune diseases with genetically modified regulatory T cells	**Jelka Pohar, PhD** National Institute of Biology
9:50-10:05	Coffee/tea break	All participants
10:05-10:25	Overcoming Challenges in the Development of Advanced Therapies- The Role of EATRIS	**David Morrow, PhD** Senior Scientific Program Manager - ATMP and VIIM Platforms, EATRIS
10:25-10:55	What is blood and who forms a haematology unit & Patient's story	**Prof. Samo Zver, PhD, MD** Head of Hematology Clinic at University Medical Center Ljubljana **Gorazd Koletnik** Patient
10:55-11:15	Pioneering access for new modalities	**Claire D'Abreu-Hayling** Chief Scientific Officer, Sandoz
11:15-11:35	Cell and Gene Therapy: Irrational Excitement or Justified Optimism?	**Patrick Bastek, PhD,** Vice President, Cell and Gene Therapy Technical R&D, Novartis
11:35-11:55	Coffee/tea break	All participants
11:55-12:45	Q&A session	**All speakers** Moderator: **Ognen Jakasanovski,** Senior Scientist PD, Sandoz development center Slovenia

Abstracts

Jelka Pohar, PhD, National Institute of Biology

Therapies for the treatment of autoimmune diseases with genetically modified regulatory T cells

Patients with autoimmune disorders often require lifelong medical interventions with severe side effects. The answer to reduce dependence on immunosuppressive drugs and to restore immune response already lies in the repertoire of our regulatory T cells (Tregs), which are essential for maintaining immune homeostasis. Several clinical and preclinical studies have demonstrated that Tregs can adequately control autoimmune responses following adoptive transfer. The clinical success of anti-cancer cell therapies, advances in genetic engineering of immune receptors, and in-depth immune profiling have simultaneously accelerated the development of more effective and safer therapeutic options.

David Morrow, PhD, Senior Scientific Program Manager - ATMP and VIIM Platforms, EATRIS

Overcoming Challenges in the Development of Advanced Therapies- The Role of EATRIS

Advanced Therapies are increasingly at the frontier of novel therapeutic approaches for many disease types, but the process of translating these new ATMPs into clinical use continues to prove difficult to navigate and requires close collaboration between many different stakeholders with valuable must have expertise. EATRIS is the European infrastructure for translational medicine. Its vision is to make the translation of scientific discoveries into medical products more effective to improve human health and quality of life and to support researchers in developing their biomedical discoveries into novel translational tools and interventions for better health outcomes for society. EATRIS provides access to a vast array of pre-clinical and clinical expertise and facilities that are available within 127+ top-tier academic centres across Europe. It focuses on improving and optimising preclinical and early clinical development of drugs, vaccines, and diagnostics. Solutions are developed in the fields of advanced therapy medicinal products, imaging and tracing, small molecules, vaccines and biomarkers. In addition, EATRIS works with public funding agencies, charities and policy makers with tailored actions to help improve the translational research and innovation ecosystem in addition to providing regulatory services, training and education and mentoring. Specifically, EATRIS the ATMP Platform supports the development of novel cell and gene therapy products by offering access to multiple GMP, preclinical and clinical facilities including patient cohorts and the required regulatory guidance for your ATMP product development. This lecture will aim to describe how EATRIS works to support academia and industry in their research needs and highlight some of the ongoing innovative projects in the ATMP space within our infrastructure.

Prof. Samo Zver, PhD, MD, Head of Hematology Clinic at University Medical Center Ljubljana

What is blood and who form haematology unit (What is blood and who forms a haematology unit)

Blood is the biggest organ in human body. And it is not even solid one but fluid one. It contains many, many different cells, similar as people are; almost look the same but in fact very different in their nature and behaviour. Main cellular blood lines are erythroid, leucocyte and platelet one. Blood is red in colour and red means vivid, restless and turbulent. And similar is haematology. Haematology ward or clinic consists of medical doctors, medical nurses, service providers, laboratory orientated and educated personal, dietician, physiotherapist, administration personal. Each working profile is a must when patients treatment is recognised as major task. One without other, we would be act each of us, on its own. So close collaboration among different fields in hematology is essential and no one deserves an underestimation.

Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz

Pioneering access for new modalities

The world of medicine is advancing rapidly. Each day, new technologies and treatment modalities are evolving – ranging from personalized medicines and cell and gene therapies to complex combination products and precision medicines. At Sandoz, our purpose is to help patients across the world access safe and effective alternatives to originator drugs at significantly lower costs thereby ensuring higher levels of adherence and better health outcomes for all. Advancements in the medical field makes our purpose even more essential for patients. What are the technologies and modalities generic companies are investing in to continue to pioneer access to these emerging treatment options? What are the capabilities and skillsets the next generation of scientists need to develop to pursue a successful career in the world of generics? Learn more during the session.

Patrick Bastek, PhD, Vice President, Cell and Gene Therapy Technical R&D, Novartis

Cell and Gene Therapy: Irrational Excitement or Justified Optimism?

Advances in cell and gene therapy have demonstrated incredible promise for patients with the potential for actual cures. Laboratory advances have placed urgency on delivering these products for patients. The development, delivery, and understanding of biological products has made remarkable progress in the last 30 years. This history can be leveraged for our future in cell and gene therapy and requires new tools, approaches, and innovations to keep up with and deliver on the promise of these therapies.